Common use of Ex-Territory Restrictions Clause in Contracts

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. (a) Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. . (b) Unless otherwise specified in this Agreement, no rights are granted under this Agreement permitting (i) manufacture or Commercialization of the Compound and/or Licensed Product outside the Territory or (ii) any other activity with respect to the Compound and/or any Licensed Product outside the Territory, and Licensee and its Affiliates agrees that they will not use the Patents or Licensed Know-How for any purpose outside the Territory. (c) Licensee and its Affiliates agree not to sell the Compound, Product Compound and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product Compound and/or the Licensed Product outside the Territory in breach of this Agreement. . (d) Licensee shall (ai) include language on the packaging of such any Licensed Product indicating that such Licensed Product is “"not for resale” " outside the initial country of sale and (bii) implement a system of batch control and tracing following the GS1 Global Traceability or comparable standards which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. . (e) If MPP or Pfizer Shionogi becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer Shionogi (itself or through MPP) shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) DocuSign Envelope ID: 76B8C7A6-66D1-43C9-84E7-0D151DB61944 shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or and/ or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or and/ or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is ““ not for resale” outside the initial country of sale and (( b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-re- exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) DocuSign Envelope ID: 91216EB2-F486-414B-B694-F90CEB5F065E shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) DocuSign Envelope ID: D912197B-D81E-47C3-A57B-57CF17C9819B shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) DocuSign Envelope ID: E68F63E3-D274-4CA3-9C96-ECE5CBD30F63 shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) DocuSign Envelope ID: 174398E9-7BC6-4D69-97DC-01A43A37BFC6 shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) DocuSign Envelope ID: E389DDA3-3EA0-4C1B-801D-93CD35BC54C2 shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. (a) Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. . (b) Unless otherwise specified in this Agreement, no rights are granted under this Agreement permitting (i) manufacture or Commercialization of the Compound and/or Licensed Product outside the Territory or (ii) any other activity with respect to the Compound and/or any Licensed Product outside the Territory, and Licensee and its Affiliates agrees that they will not use the Patents or Licensed Know-How for any purpose outside the Territory. (c) Licensee and its Affiliates agree not to sell the Compound, Product Compound and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product Compound and/or the Licensed Product outside the Territory in breach of this Agreement. . (d) Licensee shall (ai) include language on the packaging of such any Licensed Product indicating that such Licensed Product is “"not for resale” " outside the initial country of sale and (bii) implement a system of batch control and tracing following the GS1 Global Traceability or comparable standards which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. . (e) If MPP or Pfizer Shionogi becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer Shionogi (itself or through MPP) shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.. DocuSign Envelope ID: CA69B741-C435-4DB2-9D40-D4529C9174DE

Ex-Territory Restrictions. (a) Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. . (b) Unless otherwise specified in this Agreement, no rights are granted under this Agreement permitting (i) manufacture or Commercialization of the Compound and/or Licensed Product outside the Territory or ( ii) any other activity with respect to the Compound and/ or any Licensed Product outside the Territory, and Licensee and its Affiliates agrees that they will not use the Patents or Licensed Know-How for any purpose outside the Territory. (c) Licensee and its Affiliates agree not to sell the Compound, Product Compound and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product Compound and/or the Licensed Product outside the Territory in breach of this Agreement. . (d) Licensee shall (ai) include language on the packaging of such any Licensed Product indicating that such Licensed Product is “"not for resale” " outside the initial country of sale and (bii) implement a system of batch control and tracing following the GS1 Global Traceability or comparable standards which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. . (e) If MPP or Pfizer Shionogi becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (Shionogi ( itself or through MPP) shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. (a) Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. . (b) Unless otherwise specified in this Agreement, no rights are granted under this Agreement permitting (i) manufacture or Commercialization of the Compound and/or Licensed Product outside the Territory or (ii) any other activity with respect to the Compound and/or any Licensed Product outside the Territory, and Licensee and its Affiliates agrees that they will not use the Patents or Licensed Know-How for any purpose outside the Territory. (c) Licensee and its Affiliates agree not to sell the Compound, Product Compound and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product Compound and/or the Licensed Product outside the Territory in breach of this Agreement. . (d) Licensee shall (ai) include language on the packaging of such any Licensed Product indicating that such Licensed Product is “not is"not for resale” " outside the initial country of sale and (bii) implement a system of batch control and tracing following the GS1 Global Traceability or comparable standards which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. . (e) If MPP or Pfizer Shionogi becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer Shionogi (itself or through MPP) shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) DocuSign Envelope ID: F0C62F1B-BD77-4D06-9219-67924AA8E188 shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.

Ex-Territory Restrictions. Except as otherwise provided and solely in the manner permissible under this Agreement, the licenses granted are solely for the stated Territory. Licensee and its Affiliates agree not to sell the Compound, Product and/or the Licensed Product to any Third Party outside the Territory or to sell Compound and/or Licensed Product to any Third Party that Licensee or its Affiliates have reason to believe will resell the Compound, Product and/or the Licensed Product outside the Territory in breach of this Agreement. Licensee shall (a) include language on the packaging of such Licensed Product indicating that such Licensed Product is “not for resale” outside the initial country of sale and (b) implement a system of batch control and tracing which will enable the identification and batch tracing of any such Licensed Product which are subsequently re-exported outside the Territory. In addition, Licensee shall use its best efforts, including but not limited to including provisions in its customer contracts and purchase orders, to ensure that all of its customers and any subsequent purchasers of the Licensed Product in all countries of the Territory shall not sell, distribute, export or donate the Licensed Product or offer the Licensed Product for sale or donation outside the initial country of sale. If MPP or Pfizer becomes aware of any Commercialization of Licensed Product outside the Territory in breach of this Agreement, MPP or Pfizer (itself or through MPP) DocuSign Envelope ID: 20ED8EAA-71E5-4C18-B49D-62DBEC763D25 shall provide the relevant information to Licensee, and Licensee shall promptly take all possible steps to prevent any further re-exports through the distribution channel or channels identified in such information.